Central Trust Company’s ResMed RMD Stock Holding History

Central Trust Company’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$372K	Buy	1,659 +539	+48%	+$134K	0.01%	485
2025 Q4	$270K	Hold	1,120	–	–	0.01%	524
2025 Q3	$307K	Buy	1,120 +105	+10%	+$28.7K	0.01%	505
2025 Q2	$262K	Hold	1,015	–	–	0.01%	524
2025 Q1	$227K	Hold	1,015	–	–	0.01%	537
2024 Q4	$232K	Sell	1,015 -1	-0.1%	-$241	0.01%	536
2024 Q3	$248K	Sell	1,016 -39	-4%	-$8.71K	0.01%	517
2024 Q2	$202K	Sell	1,055 -115	-10%	-$23.3K	﹤0.01%	546
2024 Q1	$232K	Sell	1,170 -114	-9%	-$20.9K	0.01%	535
2023 Q4	$221K	Sell	1,284 -288	-18%	-$44.2K	0.01%	531
2023 Q3	$232K	Sell	1,572 -348	-18%	-$62.9K	0.01%	524
2023 Q2	$420K	Buy	1,920 +20	+1%	+$4.46K	0.01%	445
2023 Q1	$416K	Sell	1,900 -136	-7%	-$29.5K	0.01%	434
2022 Q4	$424K	Sell	2,036 -401	-16%	-$88.1K	0.01%	415
2022 Q3	$532K	Buy	2,437 +3	+0.1%	+$683	0.02%	367
2022 Q2	$510K	Sell	2,434 -167	-6%	-$35.6K	0.02%	371
2022 Q1	$631K	Sell	2,601 -37	-1%	-$8.95K	0.02%	377
2021 Q4	$687K	Sell	2,638 -30	-1%	-$7.79K	0.02%	390
2021 Q3	$703K	Sell	2,668 -3,199	-55%	-$875K	0.03%	372
2021 Q2	$1.45M	Buy	5,867 +3,667	+167%	+$771K	0.05%	260
2021 Q1	$427K	Sell	2,200 -5,286	-71%	-$1.06M	0.02%	409
2020 Q4	$1.59M	Buy	7,486 +3,897	+109%	+$777K	0.07%	219
2020 Q3	$615K	Sell	3,589 -504	-12%	-$93.1K	0.03%	316
2020 Q2	$786K	Sell	4,093 -681	-14%	-$111K	0.04%	269
2020 Q1	$703K	Sell	4,774 -310	-6%	-$49.4K	0.04%	270
2019 Q4	$788K	Buy	5,084 +27	+0.5%	+$3.89K	0.04%	289
2019 Q3	$683K	Sell	5,057 -70	-1%	-$9.17K	0.04%	294
2019 Q2	$639K	Buy	5,127 +5,077	+10,154%	+$562K	0.04%	297
2019 Q1	$5K	Hold	50	–	–	﹤0.01%	1001
2018 Q4	$6K	Hold	50	–	–	﹤0.01%	1015
2018 Q3	$6K	Hold	50	–	–	﹤0.01%	1107
2018 Q2	$5K	Hold	50	–	–	﹤0.01%	1117
2018 Q1	$5K	Hold	50	–	–	﹤0.01%	1130
2017 Q4	$4K	Hold	50	–	–	﹤0.01%	1121
2017 Q3	$4K	Hold	50	–	–	﹤0.01%	1091
2017 Q2	$4K	Hold	50	–	–	﹤0.01%	1089
2017 Q1	$4K	Hold	50	–	–	﹤0.01%	1062
2016 Q4	$3K	Hold	50	–	–	﹤0.01%	1112
2016 Q3	$3K	Hold	50	–	–	﹤0.01%	1069
2016 Q2	$3K	Hold	50	–	–	﹤0.01%	1100
2016 Q1	$3K	Hold	50	–	–	﹤0.01%	1069
2015 Q4	$3K	Hold	50	–	–	﹤0.01%	1108
2015 Q3	$3K	Hold	50	–	–	﹤0.01%	1126
2015 Q2	$3K	Hold	50	–	–	﹤0.01%	1144
2015 Q1	$4K	Hold	50	–	–	﹤0.01%	1096
2014 Q4	$3K	Hold	50	–	–	﹤0.01%	1130
2014 Q3	$2K	Hold	50	–	–	﹤0.01%	1146
2014 Q2	$3K	Hold	50	–	–	﹤0.01%	1110
2014 Q1	$2K	Buy	+50	New	+$2.25K	﹤0.01%	1146

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Central Trust Company's RMD Position: Q1 2026 in Review

Central Trust Company increased its ResMed (RMD) stake by 48% in Q1 2026, buying an estimated $134K and bringing the position to 1,659 shares worth $372K. The position accounts for 0.01% of the portfolio, ranked #485.

Central Trust Company first reported a position in RMD in Q1 2014 and has held it in 49 quarters since. The position peaked at $1.59M in Q4 2020. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Central Trust Company held 1,659 shares of ResMed worth $372K as of Q1 2026.
Central Trust Company bought 539 ResMed shares in Q1 2026, an estimated $134K.
ResMed made up 0.01% of Central Trust Company's portfolio in Q1 2026, its #485 holding.
Central Trust Company first reported a position in ResMed in Q1 2014 and has held it in 49 quarters since.
Central Trust Company's ResMed position peaked at $1.59M in Q4 2020.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Central Trust Company's 13F filing for Q1 2026, filed 17 Apr 2026.